Can we help you find what you're looking for?

X

Pharmacokinetics

NEXIUM is metabolized differently

NEXIUM demonstrated excellent bioavailability

NEXIUM and omeprazole bioavailability graph

Mean plasma concentration over time in patients with GERD after 5 days’ dosing*1

  • NEXIUM is the S-isomer of omeprazole, which consists of both S- and R-isomers2
  • The S- and R-isomers are metabolized differently by the liver, resulting in higher plasma levels of the S-isomer than the R-isomer, following administration of equal doses2

No cause-and-effect relationship has been established between pharmacokinetic data and clinical effectiveness.

No significant difference in clinical effectiveness has been shown between equal doses of NEXIUM and omeprazole.

Geometric mean AUC†1

NEXIUM 40 mg: 12.64 µmol/h/L
NEXIUM 20 mg: 4.18 µmol/h/L
omeprazole 20 mg: 2.34 µmol/h/L
Area under plasma concentration–time curve.
P<.0001.

*Data from a randomized, double-blind, crossover study comparing NEXIUM 40 mg, NEXIUM 20 mg, and omeprazole 20 mg, administered orally, once daily for 5 days to patients with GERD symptoms.1

 
 
NEXIUM and omeprazole bioavailability graph
 

Have a Question?

Talk to your Personal Account Specialist to get answers about NEXIUM.

Get Connected

Find Formulary Status

Search by state to find plan coverage for NEXIUM in your area.

Get Started

Sign Up

Receive updates and offers from the maker of NEXIUM.

Register Now


Important Safety Information

  • NEXIUM is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles
  • Symptomatic response to therapy does not rule out the presence of gastric malignancy
  • Atrophic gastritis has occasionally been noted with long-term therapy with omeprazole
  • Long-term and multiple daily dose proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine
  • Hypomagnesemia has been reported rarely with prolonged treatment with PPI therapy and may require discontinuing PPI therapy
  • Concomitant use of NEXIUM and St. John's wort or rifampin can substantially decrease NEXIUM concentrations. Avoid concomitant use
  • Concomitant use of NEXIUM and atazanavir or nelfinavir is not recommended. NEXIUM may increase the plasma levels of saquinavir. Dose reduction of saquinavir should be considered
  • Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time. Esomeprazole may interfere with the absorption of drugs for which gastric pH affects bioavailability (eg, ketoconazole, iron salts, and digoxin)
  • NEXIUM may increase systemic exposure of cilostazol and one of its active metabolites. Consider dose reduction
  • NEXIUM I.V. should be used only when oral therapy with NEXIUM is not possible or appropriate
  • In adults, the most frequently reported adverse reactions (ARs) with NEXIUM include headache, diarrhea, and abdominal pain
  • The ARs reported at a frequency of 1% or greater with NEXIUM I.V. in clinical trials were headache, flatulence, nausea, abdominal pain, injection site reaction, diarrhea, dry mouth, dizziness/vertigo, constipation, and pruritus
  • In pediatric patients 1 to 17 years of age, the most frequently reported ARs with NEXIUM include headache, diarrhea, abdominal pain, nausea, and somnolence

Approved Uses

NEXIUM 40 mg and 20 mg are indicated for short-term treatment (4 to 8 weeks) in healing and symptomatic resolution of diagnostically confirmed erosive esophagitis (EE). NEXIUM 20 mg is indicated to maintain symptom resolution and healing of EE (controlled studies did not extend beyond 6 months), and for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD.

References
  1. Prescribing information for NEXIUM
  2. Lind T, Rydberg L, Kylebäck A, et al. Aliment Pharmacol Ther. 2000;14:861-867.

Log In

Close
 
 
 
Remember my e-mail address Forgot Password?

Not Registered?

1488804 11/11

Forgot Your Password?

Close

To receive an e-mail with your password, please enter the e-mail address you provided for this account.

 

Return to Login

 
1488804 11/11

Password Sent

Close

You will receive a temporary password shortly. Please check your e-mail and log in again.


Return to Login

1488804 11/11

Log In

Close

You have unsuccessfully attempted to log in 3 times. If you forgot your password, click here. If you forgot the e-mail address used to create your account, call 888-692-9737, Monday through Friday, 8:30 am to 8:30 pm ET, excluding holidays.


1488804 11/11

Please Log In to Access This Content

Close

Not Registered?

Some content on AZ TouchPoints is available to registered users only. Once registered, you can use your e-mail address and password to log into any Web site powered by AZ TouchPoints.


Log In

 
Remember me Forgot Password?

1488804 11/11

Forgot Your Password?

To receive an e-mail with your password, please enter the e-mail address you provided for this account.

 

Return to Login

1488804 11/11

AZ TouchPoints Web Sites

Close
1371404 9/11

How Can We Help You?

Close

Contact an AZ Representative show/hide

If you would like information regarding products from AstraZeneca, please call

1-888-692-9737

Monday through Friday, 8:30 am to 8:30 pm ET, excluding holidays.

Have an AZ Representative Call Me show/hide

 

Sorry, there are no Personal Account Specialists currently available.

If you would like information regarding products from AstraZeneca, please call the AstraZeneca Information Center at 1-800-236-9933, Monday through Friday, 8 am to 6 pm ET, excluding holidays.

 
1488805 11/11

Visit the Suite of AZ TouchPoints Web Sites

Close